// App-Quantinova.ai

P579 : Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s disease

Researchers

Presenter

  • Derikx, L

Principal Investigators

  • Plevris, N

  • Su, S

  • Gros, B

  • Lyons, M

  • Siakavellas, S

  • Constantine-Cook, N

  • Jenkinson, P

  • O'Hare, C

  • Merchant, L

  • Noble, C

  • Arnott, I

  • Jones, G

  • Lees, C

Medical Centers

  • Radboud University Nijmegen Medical Centre, Inflammatory Bowel Disease Centre- Department of Gastroenterology and Hepatology- Route , Nijmegen, The Netherlands

  • Western General Hospital & Edinburgh University, Edinburgh, United Kingdom

  • University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom

  • University of Edinburgh, Centre for Genomics and Experimental Medicine- Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom

  • University of Edinburgh, Centre for Inflammation Research- The Queen's Medical Research Institute, Edinburgh, United Kingdom

Locations

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • Ustekinumab

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved